Research status of sperm protein 17 in breast cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZHOU Yuting , TAN Qiuwen , QIU Juanjuan ,  LÜ Qing

Breast Disease Center, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;

Corresponding author：

LÜ Qing, Email: lvqingwestchina@163.com

Keywords：

sperm protein 17; breast cancer; immunotherapy; function

DOI：

10.7507/1007-9424.201706143

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize current research status of sperm protein 17 (SP17) in breast cancer. Method Bysearching PubMed, Web of Science, CNKI, and Wanfang databases, the studies about expression and function of SP17 in the breast cancer were summarized. Results SP17 only expressed in the breast cancer tissue but not in the normal breast tissue. The result of the study showed that SP17 was only detected in the metastatic stage of tumor cells. The preclinical trails found that the breast cancer cells with SP17 positive expression could be killed by the specific T lymphocyte. Conclusions SP17 might be a potential target of immunotherapy of breast cancer, it might promote metastasis of cancer. More studies are needed to further explore its function in tumor development, thus accelerate its application in clinical practice.

Citation： ZHOU Yuting, TAN Qiuwen, QIU Juanjuan, LÜ Qing. Research status of sperm protein 17 in breast cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2018, 25(2): 242-244. doi: 10.7507/1007-9424.201706143 Copy

1.	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
2.	Chen S, Gu F, Li K, et al. A hybrid of B and T lymphoblastic cell line could potentially substitute dendritic cells to efficiently expand out Her-2/neu-specific cytotoxic T lymphocytes from advanced breast cancer patients in vitro. J Hematol Oncol, 2017, 10(1): 63.
3.	Sunay MM, Foote JB, Leatherman JM, et al. Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. Int Immunopharmacol, 2017, 46: 112-123.
4.	Salmaninejad A, Zamani MR, Pourvahedi M, et al. Cancer/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers. Immunol Invest, 2016, 45(7): 619-640.
5.	Li Y, Li J, Wang Y, et al. Roles of cancer/testis antigens (CTAs) in breast cancer. Cancer Lett, 2017, 399: 64-73.
6.	Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun, 2004, 4: 1.
7.	Grigoriadis A, Caballero OL, Hoek KS, et al. CT-X antigen expression in human breast cancer. Proc Natl Acad Sci USA, 2009, 106(32): 13493-13498.
8.	Chen YT, Ross DS, Chiu R, et al. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One, 2011, 6(3): e17876.
9.	Dong G, Loukinova E, Smith CW, et al. Genes differentially expressed with malignant transformation and metastatic tumor progression of murine squamous cell carcinoma. J Cell Biochem Suppl, 1997, 28-29: 90-100.
10.	Chiriva-Internati M, Wang Z, Salati E, et al. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood, 2002, 100(3): 961-965.
11.	Grizzi F, Gaetani P, Franceschini B, et al. Sperm protein 17 is expressed in human nervous system tumours. BMC Cancer, 2006, 6: 23.
12.	Mirandola L, Figueroa JA, Phan TT, et al. Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets. Oncotarget, 2015, 6(5): 2812-2826.
13.	Xiang SD, Gao Q, Wilson KL, et al. Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine. Vaccine, 2015, 33(44): 5950-5959.
14.	Li FQ, Liu Q, Han YL, et al. Sperm protein 17 is highly expressed in endometrial and cervical cancers. BMC Cancer, 2010, 10: 429.
15.	Pandey A, Kurup A, Shrivastava A, et al. Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol, 2012, 31(5): 302-320.
16.	Wen Y, Richardson RT, Widgren EE, et al. Characterization of Sp17: a ubiquitous three domain protein that binds heparin. Biochem J, 2001, 357(Pt 1): 25-31.
17.	Lea IA, Widgren EE, O’Rand MG. Association of sperm protein 17 with A-kinase anchoring protein 3 in flagella. Reprod Biol Endocrinol, 2004, 2: 57.
18.	Grizzi F, Franceschini B, Di Biccari S, et al. Sperm protein 17 and AKAP-associated sperm protein cancer/testis antigens are expressed in ciliated hepatic foregut cysts. Histopathology, 2015, 67(3): 398-403.
19.	Arnaboldi F, Menon A, Menegola E, et al. Sperm protein 17 is an oncofetal antigen: a lesson from a murine model. Int Rev Immunol, 2014, 33(5): 367-374.
20.	Li FQ, Han YL, Liu Q, et al. Overexpression of human sperm protein 17 increases migration and decreases the chemosensitivity of human epithelial ovarian cancer cells. BMC Cancer, 2009, 9: 323.
21.	Shang B, Gao A, Pan Y, et al. CT45A1 acts as a new proto-oncogene to trigger tumorigenesis and cancer metastasis. Cell Death Dis, 2014, 5: e1285.
22.	Song ZB, Ni JS, Wu P, et al. Testes-specific protease 50 promotes cell invasion and metastasis by increasing NF-kappaB-dependent matrix metalloproteinase-9 expression. Cell Death Dis, 2015, 6: e1703.
23.	Yang F, Zhou X, Miao X, et al. MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis. Breast Cancer Res Treat, 2014, 145(1): 23-32.
24.	Maine EA, Westcott JM, Prechtl AM, et al. The cancer-testis antigens SPANX-A/C/D and CTAG2 promote breast cancer invasion. Oncotarget, 2016, 7(12): 14708-14726.
25.	Chiriva-Internati M, Ferrari R, Yu YF, et al. Sperm protein 17 is expressed in primary and metastatic breast cancer. FASEB J, 2008, 22 (Meeting Abstract Supplement): 1079.21.
26.	Gjerstorff MF, Ditzel HJ. Limited SP17 expression within tumors diminishes its therapeutic potential. Tissue Antigens, 2012, 80(6): 523-527.
27.	Song JX, Cao WL, Li FQ, et al. Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells. Med Oncol, 2012, 29(4): 2923-2931.
28.	Chiriva-Internati M, Yu Y, Mirandola L, et al. Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One, 2010, 5(5): e10471.
29.	Xiang SD, Gao Q, Wilson KL, et al. A nanoparticle based Sp17 peptide vaccine exposes new immuno-dominant and species cross-reactive B cell epitopes. Vaccines (Basel), 2015, 3(4): 875-893.

1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
2. Chen S, Gu F, Li K, et al. A hybrid of B and T lymphoblastic cell line could potentially substitute dendritic cells to efficiently expand out Her-2/neu-specific cytotoxic T lymphocytes from advanced breast cancer patients in vitro. J Hematol Oncol, 2017, 10(1): 63.
3. Sunay MM, Foote JB, Leatherman JM, et al. Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. Int Immunopharmacol, 2017, 46: 112-123.
4. Salmaninejad A, Zamani MR, Pourvahedi M, et al. Cancer/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers. Immunol Invest, 2016, 45(7): 619-640.
5. Li Y, Li J, Wang Y, et al. Roles of cancer/testis antigens (CTAs) in breast cancer. Cancer Lett, 2017, 399: 64-73.
6. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun, 2004, 4: 1.
7. Grigoriadis A, Caballero OL, Hoek KS, et al. CT-X antigen expression in human breast cancer. Proc Natl Acad Sci USA, 2009, 106(32): 13493-13498.
8. Chen YT, Ross DS, Chiu R, et al. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One, 2011, 6(3): e17876.
9. Dong G, Loukinova E, Smith CW, et al. Genes differentially expressed with malignant transformation and metastatic tumor progression of murine squamous cell carcinoma. J Cell Biochem Suppl, 1997, 28-29: 90-100.
10. Chiriva-Internati M, Wang Z, Salati E, et al. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood, 2002, 100(3): 961-965.
11. Grizzi F, Gaetani P, Franceschini B, et al. Sperm protein 17 is expressed in human nervous system tumours. BMC Cancer, 2006, 6: 23.
12. Mirandola L, Figueroa JA, Phan TT, et al. Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets. Oncotarget, 2015, 6(5): 2812-2826.
13. Xiang SD, Gao Q, Wilson KL, et al. Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine. Vaccine, 2015, 33(44): 5950-5959.
14. Li FQ, Liu Q, Han YL, et al. Sperm protein 17 is highly expressed in endometrial and cervical cancers. BMC Cancer, 2010, 10: 429.
15. Pandey A, Kurup A, Shrivastava A, et al. Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol, 2012, 31(5): 302-320.
16. Wen Y, Richardson RT, Widgren EE, et al. Characterization of Sp17: a ubiquitous three domain protein that binds heparin. Biochem J, 2001, 357(Pt 1): 25-31.
17. Lea IA, Widgren EE, O’Rand MG. Association of sperm protein 17 with A-kinase anchoring protein 3 in flagella. Reprod Biol Endocrinol, 2004, 2: 57.
18. Grizzi F, Franceschini B, Di Biccari S, et al. Sperm protein 17 and AKAP-associated sperm protein cancer/testis antigens are expressed in ciliated hepatic foregut cysts. Histopathology, 2015, 67(3): 398-403.
19. Arnaboldi F, Menon A, Menegola E, et al. Sperm protein 17 is an oncofetal antigen: a lesson from a murine model. Int Rev Immunol, 2014, 33(5): 367-374.
20. Li FQ, Han YL, Liu Q, et al. Overexpression of human sperm protein 17 increases migration and decreases the chemosensitivity of human epithelial ovarian cancer cells. BMC Cancer, 2009, 9: 323.
21. Shang B, Gao A, Pan Y, et al. CT45A1 acts as a new proto-oncogene to trigger tumorigenesis and cancer metastasis. Cell Death Dis, 2014, 5: e1285.
22. Song ZB, Ni JS, Wu P, et al. Testes-specific protease 50 promotes cell invasion and metastasis by increasing NF-kappaB-dependent matrix metalloproteinase-9 expression. Cell Death Dis, 2015, 6: e1703.
23. Yang F, Zhou X, Miao X, et al. MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis. Breast Cancer Res Treat, 2014, 145(1): 23-32.
24. Maine EA, Westcott JM, Prechtl AM, et al. The cancer-testis antigens SPANX-A/C/D and CTAG2 promote breast cancer invasion. Oncotarget, 2016, 7(12): 14708-14726.
25. Chiriva-Internati M, Ferrari R, Yu YF, et al. Sperm protein 17 is expressed in primary and metastatic breast cancer. FASEB J, 2008, 22 (Meeting Abstract Supplement): 1079.21.
26. Gjerstorff MF, Ditzel HJ. Limited SP17 expression within tumors diminishes its therapeutic potential. Tissue Antigens, 2012, 80(6): 523-527.
27. Song JX, Cao WL, Li FQ, et al. Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells. Med Oncol, 2012, 29(4): 2923-2931.
28. Chiriva-Internati M, Yu Y, Mirandola L, et al. Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One, 2010, 5(5): e10471.
29. Xiang SD, Gao Q, Wilson KL, et al. A nanoparticle based Sp17 peptide vaccine exposes new immuno-dominant and species cross-reactive B cell epitopes. Vaccines (Basel), 2015, 3(4): 875-893.

Previous Article
The strategy of treatment and prevention of hemorrhage after radical resection of hilar cholangiocarcinoma
Next Article
Research progress of postoperative peritoneal adhesion

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research status of sperm protein 17 in breast cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content